CIK 0000875320
- Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- Operating
- EIN
- 043039129
- Phone
- +1 617-341-6393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $15,378,206
- in 4 filings, $15.4M under 10b5-1 plans
Net −$15,378,206. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-23 | Kewalramani Reshma CEO & President | Shares withheld for taxes | −9,386 | $431.79 | $4.1M | 136,507 |
| 2024-02-23 | Bozic Carmen EVP and CMO | Shares withheld for taxes | −3,309 | $431.79 | $1.4M | 36,939 |
| 2024-02-23 | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Shares withheld for taxes 10b5-1 | −1,654 | $431.79 | $714K | 16,855 |
| 2024-02-23 | Arbuckle Stuart A EVP, COO | Shares withheld for taxes 10b5-1 | −4,714 | $431.79 | $2.0M | 54,725 |
| 2024-02-23 | Ambrose Kristen SVP & Chief Accounting Officer | Shares withheld for taxes 10b5-1 | −828 | $431.79 | $358K | 8,848 |
| 2024-02-23 | ALTSHULER DAVID EVP, Global Research and CSO | Shares withheld for taxes 10b5-1 | −3,970 | $431.79 | $1.7M | 30,052 |
| 2024-02-21 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale 10b5-1 | −360 | $421.77 | $152K | 59,467 |
| 2024-02-21 | Sachdev Amit EVP Chief Patient & Ext Af Off | Sale 10b5-1 | −3,191 | $421.77 | $1.3M | 60,798 |
| 2024-02-21 | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Sale 10b5-1 | −1,201 | $421.77 | $507K | 18,509 |
| 2024-02-21 | Arbuckle Stuart A EVP, COO | Sale 10b5-1 | −3,603 | $421.77 | $1.5M | 59,439 |
| 2024-02-21 | ALTSHULER DAVID EVP, Global Research and CSO | Sale 10b5-1 | −3,002 | $421.77 | $1.3M | 34,022 |
| 2024-02-20 | WAGNER CHARLES F JR EVP & Chief Financial Officer | Shares withheld for taxes | −2,812 | $420.58 | $1.2M | 56,892 |
| 2024-02-20 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Shares withheld for taxes 10b5-1 | −3,373 | $420.58 | $1.4M | 60,307 |
| 2024-02-20 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale 10b5-1 | −480 | $420.79 | $202K | 59,827 |
| 2024-02-20 | Sachdev Amit EVP Chief Patient & Ext Af Off | Shares withheld for taxes 10b5-1 | −2,623 | $420.58 | $1.1M | 68,243 |
| 2024-02-20 | Sachdev Amit EVP Chief Patient & Ext Af Off | Sale 10b5-1 | −4,254 | $420.79 | $1.8M | 63,989 |
| 2024-02-20 | LEIDEN JEFFREY M Executive Chairman | Shares withheld for taxes | −4,118 | $420.58 | $1.7M | 13,778 |
| 2024-02-20 | Kewalramani Reshma CEO & President | Shares withheld for taxes | −7,019 | $420.58 | $3.0M | 145,893 |
| 2024-02-20 | Bozic Carmen EVP and CMO | Shares withheld for taxes | −2,812 | $420.58 | $1.2M | 40,248 |
| 2024-02-20 | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Shares withheld for taxes 10b5-1 | −1,125 | $420.58 | $473K | 20,511 |
Page 22 of 27 · 524 trades